Britsh Biotech frustrated again

Britain's battle-scarred biotech sector took another blow as questions were raised about side effects of members of the matrix metalloproteinase inhibitor (MMPI) class of drugs.

British Biotech plc and Glaxo Wellcome revealed last Friday that they were discontinuing BB-2983, a potential disease-modifying oral anti-inflammatory drug they had been developing as a treatment for arthritis and inflammatory bowel disease. Earlier in the week, Chiroscience Group plc (Cambridge, U.K.; LSE:CRO) announced that it was dropping D5410, an MMPI it was developing as a possible arthritis treatment.

British Biotech (Oxford, U.K.; LSE:BBG; NASDAQ:BBIOY) said it abandoned BB-2983, which was licensed to Glaxo in September 1995, when a long term preclinical animal toxicity study showed that the

Read the full 1209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers